Proto-oncogene tyrosine-protein kinase Src
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 253–535 | Fragment：Src kinase domain Mutation：S344N, A369S, Y418W | P01 2-({6-[(3-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol , pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K | Resolution 2.90 Å R-free 0.313 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain B； UniProt 253–535 | Fragment：Src kinase domain Mutation：S344N, A369S, Y418W | P01 2-({6-[(3-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol , pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K | Resolution 2.90 Å R-free 0.313 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1YOM | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A07 C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-MALONYL TYR-GLU-(N,N-DIPENTYL AMINE) Deposited 1997-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M MES, PH 6.5, 0.05 M CSCL, 30% JEFFAMINE M-600 AT 4 DEGREES C., pH 8.0, temperature 277K
|
Resolution 2.20 Å |
| 1A08 C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) Deposited 1997-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2.1 M AMMONIUM SULFATE AT 4 C., temperature 277K
|
Resolution 2.20 Å |
| 1A08 C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) Deposited 1997-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2.1 M AMMONIUM SULFATE AT 4 C., temperature 277K
|
Resolution 2.20 Å |
| 1A09 C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å |
| 1A09 C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å |
| 1A09 C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；277 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å |
| 1A1A C-SRC (SH2 DOMAIN WITH C188A MUTATION) COMPLEXED WITH ACE-FORMYL PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Mutation：C188S Mutation：C188S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；277 K；PROTEIN WAS CRYSTALLIZED FROM 1.0 M LI2SO4, 2% PEG8000 AT 4C. THE CRYSTAL WAS SOAKED IN 25% GLYCEROL PRIOR TO DATA COLLECTION., pH 8.0, temperature 277K
|
Resolution 2.00 Å |
| 1A1B C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；277 K；PROTEIN WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE AT 4 DEGREES C., pH 8.0, temperature 277K
|
Resolution 2.20 Å |
| 1A1C C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N-ME(-(CH2)3-CYCLOPENTYL)) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6；295 K；PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6,2M AMMONIUM SULFATE AT 22 C., temperature 295K
|
Resolution 2.40 Å |
| 1A1E C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(3-BUTYLPIPERIDINE) Deposited 1997-12-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
143–248（106 aa）
Fragment：SH2 DOMAIN
Chain B
143–248（106 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；295 K；PROTEIN WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE AT 22 DEGREES C., pH 8.0, temperature 295K
|
Resolution 2.20 Å |
| 1FMK CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC Deposited 1997-01-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
85–535（451 aa）
Fragment：RESIDUES 86-836, CONTAINING SH2, SH3, KINASE 2 DOMAINS AND C-TERMINAL TAIL
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.50 Å R-free 0.264 |
| 1HCS NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX Deposited 1994-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
143–248（106 aa）
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1HCT NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX Deposited 1994-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
143–248（106 aa）
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1KSW Structure of Human c-Src Tyrosine Kinase (Thr338Gly Mutant) in Complex with N6-benzyl ADP Deposited 2002-01-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
85–535（451 aa）
Fragment：SH3, SH2 and Kinase domains
|
Mutation：T338G Non-standard monomer：Yes (specific site not provided by mmCIF) | NBS N6-BENZYL ADENOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；12% PEG 4000, 50mM PIPES pH 6.5, 10mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.294 |
| 1O41 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 300 2-FORMYL-6-METHOXYPHENYL DIHYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O42 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU81843. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 843 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-O-PHOSPHONOTYROSINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O43 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 821 [4-((1Z)-2-(ACETYLAMINO)-3-{[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]AMINO}-3-OXOPROP-1-ENYL)-2-FORMYLPHENYL]ACET IC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.50 Å |
| 1O44 Crystal structure of sh2 in complex with ru85052 Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 852 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXY-PHENYL}-MALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O45 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 687 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3-FORMYL-O-PHOSPHONOTYROSINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.80 Å |
| 1O46 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 903 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-METHOXYCARBONYL-PHENYL}-2-FLUORO-MALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 2.00 Å |
| 1O47 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 822 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-4-[DIFLUORO(PHOSPHONO)METHYL]PHENYLALANINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.80 Å |
| 1O48 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 853 5-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXYMETHYL-BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.55 Å |
| 1O49 CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 493 {4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENOXY}-ACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O4A CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 197 4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-FORMYL-BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.50 Å |
| 1O4B CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU83876. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 876 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3,4-DIPHOSPHONOPHENYLALANINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.85 Å |
| 1O4C CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.80 Å |
| 1O4D CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78262. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 262 2-FORMYLPHENYL DIHYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.85 Å |
| 1O4E CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78299. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 299 2,6-DIFORMYL-4-METHYLPHENYL DIHYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 2.00 Å |
| 1O4F CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 790 1,2,3,4-TETRAHYDROQUINOLIN-8-YL DIHYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 2.00 Å |
| 1O4G CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | I59 HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.55 Å |
| 1O4H CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 772 2-CYANOQUINOLIN-8-YL DIHYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 2.25 Å |
| 1O4I CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 219 cyclohexylmethyl 2-formylphenyl hydrogen (S)-phosphate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.75 Å |
| 1O4J CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH ISO24. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | IS2 [(4-ETHYLPHENYL)AMINO]CARBONYLPHOSPHONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O4K CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | PSN BENZYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.57 Å |
| 1O4L CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | CIT CITRIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.65 Å |
| 1O4M CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | MLA MALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.60 Å |
| 1O4N CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH OXALIC ACID. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | OXD OXALIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.60 Å |
| 1O4O CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHENYLPHOSPHATE. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | HPS PHENYL DIHYDROGEN PHOSPHATE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O4P CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78791. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 791 2-PHENYLMALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.90 Å |
| 1O4Q CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79256. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 256 PHENYL(SULFO)ACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.70 Å |
| 1O4R CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78783. Deposited 2003-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–251（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | 787 (PHENYL-PHOSPHONO-METHYL)-PHOSPHONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.50
|
Resolution 1.50 Å |
| 1SHD PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONS Deposited 1994-11-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
143–248（106 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å |
| 1Y57 Structure of unphosphorylated c-Src in complex with an inhibitor Deposited 2004-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
86–536（451 aa）
Fragment：SH3 SH2 and KINASE domains
|
Not recorded | SO4 SULFATE ION × 5 MPZ 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-N-{3-[(4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO]PHENYL}BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；ammonium sulfate, tris, glycerol, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.91 Å R-free 0.213 |
| 1YI6 C-term tail segment of human tyrosine kinase (258-533) Deposited 2005-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
260–535（276 aa）
Fragment：residues 258-533
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；PEG 6000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.252 |
| 1YI6 C-term tail segment of human tyrosine kinase (258-533) Deposited 2005-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
260–535（276 aa）
Fragment：residues 258-533
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；PEG 6000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.252 |
| 1YOJ Crystal structure of Src kinase domain Deposited 2005-01-27 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
253–535（283 aa）
Fragment：Src kinase domain
|
Mutation：S344N, A369S, Y418W | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 1.95 Å R-free 0.258 |
| 1YOJ Crystal structure of Src kinase domain Deposited 2005-01-27 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
253–535（283 aa）
Fragment：Src kinase domain
|
Mutation：S344N, A369S, Y418W | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 1.95 Å R-free 0.258 |
| 1YOL Crystal structure of Src kinase domain in complex with CGP77675 Deposited 2005-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
253–535（283 aa）
Fragment：SRC KINASE DOMAIN
|
Mutation：S344N, A369S | S03 1-{4-[4-AMINO-5-(3-METHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL]BENZYL}PIPERIDIN-4-OL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.30 Å R-free 0.247 |
| 1YOL Crystal structure of Src kinase domain in complex with CGP77675 Deposited 2005-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
253–535（283 aa）
Fragment：SRC KINASE DOMAIN
|
Mutation：S344N, A369S | S03 1-{4-[4-AMINO-5-(3-METHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL]BENZYL}PIPERIDIN-4-OL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.30 Å R-free 0.247 |
| 2BDF Src kinase in complex with inhibitor AP23451 Deposited 2005-10-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
257–535（279 aa）
Fragment：kinase domain
|
Not recorded | 24A {[(4-{[2-(4-AMINOCYCLOHEXYL)-9-ETHYL-9H-PURIN-6-YL]AMINO}PHENYL)(HYDROXY)PHOSPHORYL]METHYL}PHOSPHONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15% PEG400, 50mM NaCl, 100mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.271 |
| 2BDF Src kinase in complex with inhibitor AP23451 Deposited 2005-10-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
257–535（279 aa）
Fragment：kinase domain
|
Not recorded | 24A {[(4-{[2-(4-AMINOCYCLOHEXYL)-9-ETHYL-9H-PURIN-6-YL]AMINO}PHENYL)(HYDROXY)PHOSPHORYL]METHYL}PHOSPHONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15% PEG400, 50mM NaCl, 100mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.271 |
| 2BDJ Src kinase in complex with inhibitor AP23464 Deposited 2005-10-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
257–535（279 aa）
Fragment：kinase domain
|
Not recorded | HET 3-[2-(2-CYCLOPENTYL-6-{[4-(DIMETHYLPHOSPHORYL)PHENYL]AMINO}-9H-PURIN-9-YL)ETHYL]PHENOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.3；298 K；20% PEG3350, 200mM NH4NO3, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å R-free 0.277 |
| 2H8H Src kinase in complex with a quinazoline inhibitor Deposited 2006-06-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–535（535 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | H8H N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；288 K；50 mM PIPES pH 6.5, 10 mM DTT, 100 mM sodium chloride and 4 to 9% PEG4000 (w/v), VAPOR DIFFUSION, SITTING DROP, temperature 288K
|
Resolution 2.20 Å R-free 0.272 |
| 2SRC CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC, IN COMPLEX WITH AMP-PNP Deposited 1998-12-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
85–535（451 aa）
Fragment：RESIDUES 86-836, CONTAINING SH2, SH3, KINASE 2 DOMAINS AND C-TERMINAL TAIL
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；pH 6.5
|
Resolution 1.50 Å R-free 0.281 |
| 3VRO Crystal structure of the tyrosine kinase binding domain of Cbl-c in complex with phospho-Src peptide Deposited 2012-04-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
412–424（13 aa）
Fragment：phospho-Src peptide, residues 412-424
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10% PEG3350, 0.1M ammonium formate, 0.1M NDSB-201, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.212 |
| 3ZMP Src-derived peptide inhibitor complex of PTP1B Deposited 2013-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
527–536（10 aa）
Fragment：RESIDUES 527-536
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 27.14W/V% PEG3350, 0.1M HEPES, PH=7.5
|
Resolution 2.62 Å R-free 0.271 |
| 3ZMP Src-derived peptide inhibitor complex of PTP1B Deposited 2013-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
527–536（10 aa）
Fragment：RESIDUES 527-536
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 27.14W/V% PEG3350, 0.1M HEPES, PH=7.5
|
Resolution 2.62 Å R-free 0.271 |
| 3ZMQ Src-derived mutant peptide inhibitor complex of PTP1B Deposited 2013-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
527–536（10 aa）
Fragment：PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC RESIDUES 527-536
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 0.1M TRIS-HCL, PH=8.5 30% (W/V)POLYETHYLENE GLYCOL 4000
|
Resolution 3.30 Å R-free 0.304 |
| 4F59 Triple mutant Src SH2 domain Deposited 2012-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–252（109 aa）
Fragment：SH2 domain
|
Mutation：T183V/C188A/K206L | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；277 K；0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.71 Å R-free 0.246 |
| 4F5A Triple mutant Src SH2 domain bound to phosphate ion Deposited 2012-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–252（109 aa）
Fragment：SH2 domain
|
Mutation：T183V/C188A/K206L | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；277 K；0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.80 Å R-free 0.245 |
| 4F5B Triple mutant Src SH2 domain bound to phosphotyrosine Deposited 2012-05-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
144–252（109 aa）
Fragment：SH2 domain
|
Mutation：T183V/C188A/K206L | PTR O-PHOSPHOTYROSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；277 K；0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.57 Å R-free 0.230 |
| 4HXJ Crystal structure of SH3:RGT complex Deposited 2012-11-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
87–144（58 aa）
Fragment：human c-Src SH3 domain, UNP residues 87-144
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；100mM Tris, pH 8.0, 1.3M sodium citrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.193 |
| 4HXJ Crystal structure of SH3:RGT complex Deposited 2012-11-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
87–144（58 aa）
Fragment：human c-Src SH3 domain, UNP residues 87-144
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；100mM Tris, pH 8.0, 1.3M sodium citrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.193 |
| 4K11 The structure of 1NA in complex with Src T338G Deposited 2013-04-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
87–534（448 aa）
Fragment：UNP residues 87-534
|
Mutation：T338G Non-standard monomer：Yes (specific site not provided by mmCIF) | 0J9 1-tert-butyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；50 mM PIPES, pH 6.5, 12% PEG4000, 10 mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.246 |
| 4MXO human Src kinase bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Not recorded | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.254 |
| 4MXO human Src kinase bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Not recorded | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.254 |
| 4MXX Human Src A403T mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：A403T | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M Ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.60 Å R-free 0.276 |
| 4MXX Human Src A403T mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：A403T | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M Ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.60 Å R-free 0.276 |
| 4MXY Src M314L T338M double mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：M314L T338M | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å R-free 0.266 |
| 4MXY Src M314L T338M double mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：M314L T338M | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å R-free 0.266 |
| 4MXZ Src M314L T338M double mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：M314L, T338M | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å R-free 0.266 |
| 4MXZ Src M314L T338M double mutant bound to kinase inhibitor bosutinib Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
254–536（283 aa）
Fragment：Kinase domain, UNP residues 254-536
|
Mutation：M314L, T338M | DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å R-free 0.266 |
| 6ATE SRC kinase bound to covalent inhibitor Deposited 2017-08-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
|
Not recorded | 6H3 N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1 M MES, pH 6.5, 16%-20% PEG 3350, 350 mM - 420mM NaOAc
|
Resolution 2.40 Å R-free 0.228 |
| 6C4S Human cSrc SH3 Domain in complex with Choline Kinase fragment 60-69 Deposited 2018-01-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
87–144（58 aa）
Fragment：SH3 domain residues 87-144
Chain B
87–144（58 aa）
Fragment：SH3 domain residues 87-144
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M Zinc Acetate
0.1 M Sodium Cacodylate pH 6.5
10% v/v Isopropanol
|
Resolution 1.50 Å R-free 0.226 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain E
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain F
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain G
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 6E6E DGY-06-116, a novel and selective covalent inhibitor of SRC kinase Deposited 2018-07-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain H
261–536（276 aa）
|
Not recorded | HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å R-free 0.285 |
| 7NG7 Src kinase bound to eCF506 trapped in inactive conformation Deposited 2021-02-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 UCW tert-butyl (4-(4-amino-1-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)carbamate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；6% PEG3350, 300mM Ammonium acetate, 0.1M HEPES pH7.5, 10mM TCEP
|
Resolution 1.50 Å R-free 0.213 |
| 7OTE Src Kinase Domain in complex with ponatinib Deposited 2021-06-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
254–536（283 aa）
|
Not recorded | 0LI 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide × 1 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；Tris 20 mM pH 8, 150 mM Sodium chloride, 1 mM DTT, 2-propanol and PEG 4.000
|
Resolution 2.49 Å R-free 0.252 |
| 7OTE Src Kinase Domain in complex with ponatinib Deposited 2021-06-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
254–536（283 aa）
|
Not recorded | 0LI 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide × 1 GOL GLYCEROL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；Tris 20 mM pH 8, 150 mM Sodium chloride, 1 mM DTT, 2-propanol and PEG 4.000
|
Resolution 2.49 Å R-free 0.252 |
| 7T1U Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide Deposited 2021-12-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
147–251（105 aa）
Fragment：SH2 domain
|
Mutation：Residues 180 to 188 mutated from SETTKGAYC to GQSQPDYV and K206I (numbered as residue 205 in these coordinates) | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；80 uM Zinc Acetate, 12% PEG3350, 100 mM Sodium Acetate (pH 4.0), and 2% 1,3-butanediol
|
Resolution 2.65 Å R-free 0.270 |
| 7T1U Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide Deposited 2021-12-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
147–251（105 aa）
Fragment：SH2 domain
|
Mutation：Residues 180 to 188 mutated from SETTKGAYC to GQSQPDYV and K206I (numbered as residue 205 in these coordinates) | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；293 K；80 uM Zinc Acetate, 12% PEG3350, 100 mM Sodium Acetate (pH 4.0), and 2% 1,3-butanediol
|
Resolution 2.65 Å R-free 0.270 |
| 7YQE Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54. Deposited 2022-08-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
85–247（163 aa）
|
Mutation：C338S,C340S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1% v/v 1,4 Dioxane, 0.1 M Tris pH 7.5, 12.5% w/v Polyethylene glycol 3,350
|
Resolution 3.50 Å R-free 0.295 |
| 7YQE Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54. Deposited 2022-08-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
85–247（163 aa）
|
Mutation：C338S,C340S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1% v/v 1,4 Dioxane, 0.1 M Tris pH 7.5, 12.5% w/v Polyethylene glycol 3,350
|
Resolution 3.50 Å R-free 0.295 |
| 8HAQ The complex of Src with GW8510 Deposited 2022-10-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
266–542（277 aa）
|
Not recorded | L1N 4-[(~{E})-(7-oxidanyl-6~{H}-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-~{N}-pyridin-2-yl-benzenesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M MOPS pH 7.0, 18% PEG 3350, 5% Glycerol, 5 mM TCEP
|
Resolution 2.27 Å R-free 0.250 |
| 8HAQ The complex of Src with GW8510 Deposited 2022-10-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
266–542（277 aa）
|
Not recorded | L1N 4-[(~{E})-(7-oxidanyl-6~{H}-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-~{N}-pyridin-2-yl-benzenesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M MOPS pH 7.0, 18% PEG 3350, 5% Glycerol, 5 mM TCEP
|
Resolution 2.27 Å R-free 0.250 |
| 8JF3 C-Src in complex with compound 9 Deposited 2023-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
254–536（283 aa）
Chain B
254–536（283 aa）
|
Not recorded | C0N 2-[4-[4-[bis(oxidanylidene)-$l^5-sulfanyl]oxyphenyl]carbonylpiperazin-1-yl]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-prop-2-ynyl-pyrimidine-4-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；300 mM Sodium Acetate, 0.1 M MES pH 7.5, 4% PEG3350
|
Resolution 2.85 Å R-free 0.317 |
| 8JN8 Crystal structure of c-Src in complex with covalent inhibitor DC-Srci-6668 Deposited 2023-06-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–536（536 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | JA6 (2R)-N-cyclopentyl-2-[cyclopropyl(ethanoyl)amino]-2-(4-fluorophenyl)ethanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；0.2M tri-Lithium citrate, 20%(w/v) PEG 3350
|
Resolution 1.90 Å R-free 0.254 |
| 8JN9 Crystal structure of c-Src in complex with covalent inhibitor LW-Srci-8 Deposited 2023-06-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–536（536 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | UJ0 N-[(1R)-1-[3,5-bis(fluoranyl)phenyl]-2-(cyclopentylamino)-2-oxidanylidene-ethyl]-N-cyclopropyl-prop-2-enamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；0.2M tri-Lithium citrate, 20%(w/v) PEG 3350
|
Resolution 2.72 Å R-free 0.279 |
| 8VCF Crystal structure of Superbinder Src SH2 domain with Cysteine to Serine mutations Deposited 2023-12-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
161–268（108 aa）
Fragment：SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；VAPOR DIFFUSION,SITTING DROP, TEMPERATURE 290K
0.2 M Ammonium Fluoride, 20% PEG 3350
|
Resolution 1.50 Å R-free 0.177 |
| 8VCG Mutant Src SH2 domain in complex with phosphotyrosine Deposited 2023-12-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
161–267（107 aa）
Fragment：SH2 DOMAIN
|
Not recorded | PTR O-PHOSPHOTYROSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；VAPOR DIFFUSION,
SITTING DROP, TEMPERATURE 290K
0.2 M Ammonium Fluoride, 20% PEG 3350
|
Resolution 1.61 Å R-free 0.176 |
| 9IRL Crystal structure analysis of LW-Srci-2o in complex with c-Src. Deposited 2024-07-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
86–536（451 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | A1L20 (2~{R})-2-[3,5-bis(fluoranyl)phenyl]-2-[2-chloranylethanoyl(cyclopropyl)amino]-~{N}-cyclopentyl-ethanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；PEG 3350, Hepes 7.4
|
Resolution 2.03 Å R-free 0.243 |
| 9NS0 Ground state of Src kinase domain Deposited 2025-03-14 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
251–536（286 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；298 K；Ionic strength (raw mmCIF value) 500；Pressure 1
NMR sample composition
250 uM [U-15N; U-2H] ILVMAT CH3 FY CEHE Proto-oncogene tyrosine-protein kinase Src, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
250 uM [U-13C; U-15N; U-2H] Proto-oncogene tyrosine-protein kinase Src, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 9NS1 Intermediate state of Src kinase domain Deposited 2025-03-15 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
251–536（286 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；303 K；Ionic strength (raw mmCIF value) 500；Pressure 1
NMR sample composition
250 uM [U-13C; U-15N; U-2H] SrcA311I kinase, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
250 uM [U-15N; U-2H] ILVMAT CH3 FY CEHE SrcA311I kinase, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 9OFX Crystal structure of c-Src SH3 domain in H32 space group mediated by nickel Deposited 2025-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
85–143（59 aa）
Fragment：c-Src SH3 domain
Chain B
85–143（59 aa）
Fragment：c-Src SH3 domain
Chain C
85–143（59 aa）
Fragment：c-Src SH3 domain
Chain D
85–143（59 aa）
Fragment：c-Src SH3 domain
|
Not recorded | NI NICKEL (II) ION × 2 GOL GLYCEROL × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.7 M Ammonium Sulfate, 5 mM NiCl2, 10% glycerol, 0.1 M HEPES pH 7.5
|
Resolution 1.45 Å R-free 0.196 |
76 other PDB entries and 100 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | SRC_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–283； UniProt 253–535 Author chain B； PDBConstruct 1–283； UniProt 253–535 |
